Chemistry:AVN-397
From HandWiki
AVN-397 is a 5-hydroxytryptamine subtype 6 receptor antagonist drug developed by Avineuro Pharmaceuticals Inc. that can potentially be used to treat Alzheimer's disease and general anxiety disorder (GAD).[1][2] Avineuro announced that it would start Phase II clinical trials in 2009, and those trials were ongoing as of 2012.[3][4][5]Phase II trials are now listed as Discontinued.[6][7]
References
- ↑ Griebel, Guy; Holmes, Andrew (2013). "50 years of hurdles and hope in anxiolytic drug discovery" (in en). Nature Reviews Drug Discovery 12 (9): 667–687. doi:10.1038/nrd4075. ISSN 1474-1776. PMID 23989795.
- ↑ "AVN 397 - AdisInsight". https://adisinsight.springer.com/drugs/800031584.
- ↑ "Avineuro Announces Beginning Of Phase II Clinical Studies Of AVN-397, Potent Small Molecule For Treatment Of Anxiety And Alzheimer's Disease" (in en-US). https://www.biospace.com/article/avineuro-announces-beginning-of-phase-ii-clinical-studies-of-avn-397-potent-small-molecule-for-treatment-of-anxiety-and-alzheimer-s-disease-/.
- ↑ Froestl, W.; Pfeifer, A.; Muhs, A. (2014). "Cognitive enhancers (Nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. Update 2014." (in en). Journal of Alzheimer's Disease 42 (4): 1079–1149. doi:10.3233/JAD-141206. PMID 25061058. https://docksci.com/cognitive-enhancers-nootropics-part-3-drugs-interacting-with-targets-other-than-_5ac80245d64ab28156615f13.html. Retrieved 2023-03-12.
- ↑ Medicines in Development / Mental Illnesses / 2012 Report, https://www.leg.state.nv.us/Session/77th2013/Exhibits/Senate/JUD/SJUD399E.pdf
- ↑ "Search for drugs | Therapeutic Target Database". https://db.idrblab.net/ttd/search/ttd/drug?search_api_fulltext=AVN-397.
- ↑ "Delving into the Latest Updates on AVN-397 with Synapse" (in en). https://synapse.patsnap.com/drug/8574f865018f4783a13427d9eeccc13a?utm_source=chatgpt.com.
 |  |
